Patent · US Active

Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

US11371024B2 · kind B2 · utility

2Cited by

2References

17Claims

0Family size

Assignees

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US
The Research Foundation for The State University of New York · US

Inventors

Peter L. Collins · Kensington, US
Cyril Le Nouen · Bethesda, US
Linda G. Brock · Wyckoff, US
Ursula Buchholz · Silver Spring, US
Joshua Marc DiNapoli · Lexington, US
Steffen Mueller · Pforzheim, DE
Eckard Wimmer · Port Jefferson, US

Key dates

Filing date	Mar 16, 2018
Grant date	Jun 28, 2022
Priority date	—
Expiry date	Mar 16, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18562
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.